Table 2 Clinical characteristics of non-COVID-19 explanted heart cohort

N

47

93

/

Mean age (years)

52.9±6.7

53.7±4.1

0.19

Sex, male (%)

35 (74)

73 (78)

0.36

BMI (kg/m²)

27.3±1.2

25.7±1.6

0.001

Aetiology of heart failure, n (%)

 Ischemic cardiomyopathy

25 (53)

50 (54)

0.54

 Dilated cardiomyopathy

20 (42)

37 (40)

0.27

 Other

2 (4)

6 (6)

0.33

Cardiovascular risk factors, n (%)

 Hypertension, n (%)

12 (25)

25 (27)

0.52

 Dyslipidemia, n (%)

21 (45)

30 (32)

0.10

 Family history of CAD, n (%)

27 (57)

45 (48)

0.20

 Smoking history, n (%)

5 (11)

10 (11)

0.61

Laboratory analyses

 Plasma glucose (mg/dl)

126.7±18.7

88.7±6.7

0.001

 HbA1c (%)

6.7±1.2

4.8±0.8

0.007

 Cholesterol (mg/dl)

177.1±21.6

161.7±18.7

0.011

 LDL-cholesterol (mg/dl)

101.1±22.7

97.4±16.7

0.16

 HDL-cholesterol (mg/dl)

40.9±1.1

41.8±1.7

0.21

 Triglycerides (mg/dl)

172.4±28.2

113.4±11.1

0.013

 Creatinine (mg/dl)

1.0±0.37

1.0±0.26

0.74

Therapy

 ACEi, n (%)

40 (85)

83 (89)

0.33

 ARBs, n (%)

15 (32)

34 (37)

0.36

 Diuretic, n (%)

45 (96)

92 (99)

0.26

 Antiaggregant, n (%)

46 (98)

83 (89)

0.06

 Anticoagulant, n (%)

5 (11)

16 (17)

0.22

 Statin, n (%)

40 (85)

70 (75)

0.12

 Beta-blockers, n (%)

47 (100)

90 (97)

0.55

 Sacubitril-valsartan, n (%)

21 (45)

31 (33)

0.13

 Nitrate, n (%)

21 (45)

37 (40)

0.35

 Calcium-antagonist, n (%)

7 (15)

6 (6)

0.96